Ionis Pharmaceuticals (IONS) Price & Analysis

Compare

1,374 Followers

IONS Stock Chart & Stats

Day’s Range― - ―

52-Week Range$0.00 - $0.00

Previous CloseN/A

Volume126.35K

Average Volume (3M)1.98M

Market Cap

$0.00

Enterprise Value$0.00

Total Cash (Recent Filing)$2.15B

Total Debt (Recent Filing)$1.41B

Price to Earnings (P/E)―

Beta0.00

Next Earnings

Oct 30, 2025

EPS Estimate

-1.2

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.70

Shares Outstanding0

10 Day Avg. Volume2,017,712

30 Day Avg. Volume1,975,119

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market CapN/A

Enterprise Value/Revenue0.00

Enterprise Value/Gross Profit0.00

Enterprise Value/Ebitda0.00

Forecast

1Y Price Target

$58.12

Price Target Upside35.01% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering19

Bulls Say, Bears Say

Bulls Say

Clinical TrialsAnalysts believe that the bar for clinical success of olezarsen in reducing triglyceride levels is achievable, which could lead to a breakthrough opportunity.

Drug Launch SuccessThe launch of the new drug Tryngolza significantly exceeded sales expectations, indicating strong market demand.

Financial GuidanceIONS announced 2Q25 results and raised FY25 guidance by ~$100mm to $825mm-$850mm.

Bears Say

Clinical Data UncertaintyThe most heated controversy is whether Ionis will show AP risk reduction in the sHTG Ph3 topline, expected in September.

Market Growth ConcernsManagement commentary suggests growth will slow from here, with the focus shifting to patient finding after spending 1H25 focused on converting trial participants to commercial drug.

Revenue RiskTRYNGOLZA's price is expected to drop from FCS rare pricing of $595k to $10-20k per year after sHTG approval, potentially risking a temporary stunt in TRYNGOLZA revenues.

Ionis Pharmaceuticals News

Ionis Pharmaceuticals price target raised to $65 from $50 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Ionis Pharmaceuticals (IONS) to $65 from $50 and keeps a...

7d ago

IONS

Ionis upgraded to Overweight from Equal Weight at Morgan Stanley

Morgan Stanley upgraded Ionis Pharmaceuticals (IONS) to Overweight from Equal Weight with a price target of $62, up...

7d ago

IONS

Morgan Stanley upgrades Ionis to Overweight on Tryngolza momentum

Morgan Stanley upgraded Ionis Pharmaceuticals (IONS) to Overweight from Equal Weight with a price target of $62, up...

7d ago

IONS

Ionis Pharmaceuticals raises FY25 revenue view to $825M-$850M from $725M-$750M

Consensus $755.78M. Sees FY25 Tryngolza revenue $75M-$80M. “For the second time this year, we are significantly raising our...

8d ago

IONS

Ionis Pharmaceuticals reports Q2 EPS 70c, consensus 16c

Reports Q2 revenue $452M, consensus $298.99M. Revenue doubled in the second quarter of 2025 and increased nearly 70%...

8d ago

IONS

Barclays says Merck/AstraZeneca earnings neutral to Moderna, negative to Ionis

Barclays analyst Gena Wang notes that Merck (MRK) and AstraZeneca (AZN) reported Q2 earnings, which the firm sees...

8d ago

AZN

MRK

Ionis Pharmaceuticals announces CHMP opinion recommending Tryngolza

Ionis Pharmaceuticals (IONS) announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency...

13d ago

IONS

Ionis Pharmaceuticals publishes results of OASISplus study

Ionis Pharmaceuticals (IONS) announced that results from the Phase 3 OASISplus prospective switch study of donidalorsen in patients...

17d ago

IONS

Positive Outlook for Ionis Pharmaceuticals Driven by Strong Q2 Results and Promising Pipeline Developments

Leerink Partners analyst Mani Foroohar has maintained their bullish stance on IONS stock, giving a Buy rating yesterday....

6d ago

IONS

Ionis Pharmaceuticals Reports Strong Earnings and Growth

Ionis Pharmaceuticals Inc. (($IONS)) has held its Q2 earnings call. Read on for the main highlights of the...

6d ago

IONS

Ionis Pharmaceuticals: Hold Rating Amid Strong Performance and Future Uncertainties

Analyst William Pickering of Bernstein maintained a Hold rating on Ionis Pharmaceuticals, with a price target of $42.00....

7d ago

IONS

Ionis Pharmaceuticals: Strong Q2 Performance and Promising Future Catalysts Justify Buy Rating

Ionis Pharmaceuticals, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Jason Gerberry from...

7d ago

IONS

Ionis Pharmaceuticals: Strong Financial Performance and Strategic Growth Drive Buy Rating

Yanan Zhu, an analyst from Wells Fargo, maintained the Buy rating on Ionis Pharmaceuticals. The associated price target...

7d ago

IONS

Ionis Pharmaceuticals Reports Strong Q2 2025 Results

Ionis Pharmaceuticals Inc. ( ($IONS) ) has released its Q2 earnings. Here is a breakdown of the information...

7d ago

IONS

IONS FAQ

What was Ionis Pharmaceuticals Inc.’s price range in the past 12 months?

Ionis Pharmaceuticals Inc. lowest stock price was $0.00 and its highest was $0.00 in the past 12 months.

What is Ionis Pharmaceuticals Inc.’s market cap?

Ionis Pharmaceuticals Inc.’s market cap is $0.00.

When is Ionis Pharmaceuticals Inc.’s upcoming earnings report date?

Ionis Pharmaceuticals Inc.’s upcoming earnings report date is Oct 30, 2025 which is in 84 days.

How were Ionis Pharmaceuticals Inc.’s earnings last quarter?

Ionis Pharmaceuticals Inc. released its earnings results on Jul 30, 2025. The company reported $0.7 earnings per share for the quarter, beating the consensus estimate of -$0.091 by $0.791.

Is Ionis Pharmaceuticals Inc. overvalued?

According to Wall Street analysts Ionis Pharmaceuticals Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Ionis Pharmaceuticals Inc. pay dividends?

Ionis Pharmaceuticals Inc. does not currently pay dividends.

What is Ionis Pharmaceuticals Inc.’s EPS estimate?

Ionis Pharmaceuticals Inc.’s EPS estimate is -1.2.

How many shares outstanding does Ionis Pharmaceuticals Inc. have?

Ionis Pharmaceuticals Inc. has 0 shares outstanding.

What happened to Ionis Pharmaceuticals Inc.’s price movement after its last earnings report?

Ionis Pharmaceuticals Inc. reported an EPS of $0.7 in its last earnings report, beating expectations of -$0.091. Following the earnings report the stock price went up 4.556%.

Which hedge fund is a major shareholder of Ionis Pharmaceuticals Inc.?

Currently, no hedge funds are holding shares in IONS

Ionis Pharmaceuticals Stock Smart Score

Neutral

Fundamentals

Return on Equity

-59.83%

Trailing 12-Months

Asset Growth

10.92%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Ionis Pharmaceuticals Inc.

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of TTR amyloidosis; Olezarsen for patients with severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Tofersen to inhibit the production of superoxide dismutase 1. In addition, the company develops medicines for metabolic diseases, infectious diseases, renal diseases, ophthalmic diseases, and cancer. It has a strategic collaboration with Biogen Inc.; and collaboration and license agreement with AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis AG, Roche, Janssen Biotech, Inc., and Flamingo Therapeutics, Inc. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California.

Ionis Pharmaceuticals (IONS) Earnings & Revenues

Historic Earnings Reports

IONS Company Deck

IONS Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call reflects a strong overall performance with significant revenue growth, successful product launches, and positive pipeline developments. However, challenges in patient identification and pricing strategy, along with uncertainties in data outcomes, present areas of concern.View all IONS earnings summaries

IONS Revenue Breakdown

60.82% R&D

39.18% Commercial

IONS Stock 12 Month Forecast

Average Price Target

$58.12

▲(35.01% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"26":"$26","79":"$79","39.25":"$39.3","52.5":"$52.5","65.75":"$65.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":78,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$78.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":58.12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$58.12</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":38,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$38.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[26,39.25,52.5,65.75,79],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,43.03,45.72,48.410000000000004,51.1,53.79,56.480000000000004,59.17,61.86,64.55,67.24000000000001,69.93,72.62,75.31,{"y":78,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,43.03,44.190769230769234,45.35153846153846,46.512307692307694,47.67307692307692,48.83384615384615,49.994615384615386,51.15538461538462,52.316153846153846,53.47692307692307,54.637692307692305,55.79846153846154,56.95923076923077,{"y":58.12,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,43.03,42.643076923076926,42.25615384615385,41.86923076923077,41.48230769230769,41.09538461538462,40.70846153846154,40.32153846153846,39.934615384615384,39.54769230769231,39.16076923076923,38.77384615384615,38.386923076923075,{"y":38,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":51.32,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.68,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.07,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.76,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.1,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.96,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.9,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.19,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.26,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.71,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.11,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.94,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.03,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >